

## **Galapagos increases share capital through warrant exercises**

**Mechelen, Belgium; 20 June 2019, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from warrant exercises.**

Galapagos issued 208,310 new ordinary shares on 20 June 2019, for a total capital increase (including issuance premium) of €4,325,094.48.

Pursuant to the warrant exercise program of Galapagos' executive committee, executive committee members automatically are committed to exercise a minimum number of warrants, subject to certain conditions. In accordance with the rules of this program, CEO Onno van de Stolpe exercised 15,000 warrants. Three other executive committee members exercised an aggregate number of 45,000 warrants.

In accordance with Belgian transparency legislation<sup>1</sup>, Galapagos notes that its total share capital currently amounts to €296,534,760.91, the total number of securities conferring voting rights is 54,823,101, which is also the total number of voting rights (the "denominator"), and all securities conferring voting rights and all voting rights are of the same category. The total number of rights (warrants) to subscribe to not yet issued securities conferring voting rights is 4,258,602 which equals the total number of voting rights that may result from the exercise of these warrants. Galapagos does not have any convertible bonds or shares without voting rights outstanding.

### **About Galapagos**

Galapagos (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, osteoarthritis and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at [www.glpg.com](http://www.glpg.com).

### **Contacts**

#### **Investors:**

Elizabeth Goodwin  
VP Investor Relations  
+1 781 460 1784

Sofie Van Gijsel  
Director IR  
+32 485 19 14 15  
[ir@glpg.com](mailto:ir@glpg.com)

#### **Media:**

Carmen Vroonen  
Senior Director Communications & Public Affairs  
+32 473 824 874

Evelyn Fox  
Director Communications  
+31 6 53 591 999  
[communications@glpg.com](mailto:communications@glpg.com)

---

<sup>1</sup> Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market

**Forward-looking statements**

*This release may contain forward-looking statements. Such forward-looking statements are not guarantees of future results. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any forward-looking statements in this document, unless specifically required by law or regulation.*